ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,322.80
-1.15%
S&P ASX All Technology
4,098.90
-0.80%
Brent Oil
76.21
0.51%
US Dollar vs AUD
1.56521
-0.76%
Bitcoin
97,220.87
0.61%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Omeros Corporation (OMER)

  7. Omeros Corporation (OMER) News

OMER

Omeros (OMER)

Omeros Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:OMER
DateTimeSourceHeadlineSymbolCompany
21/02/202501:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
21/02/202501:10Business WireOmeros Announces Robust Results for Narsoplimab Expanded Access Program in TA-TMANASDAQ:OMEROmeros Corporation
15/02/202501:00Business WireOmeros Corporation Announces Availability on its Website of Materials Accompanying Narsoplimab Presentations at the 2025 Tandem MeetingsNASDAQ:OMEROmeros Corporation
11/02/202501:00Business WireOmeros Corporation Announces Upcoming Presentations Detailing Outcomes of Narsoplimab Treatment for TA-TMA Under an Expanded Access ProgramNASDAQ:OMEROmeros Corporation
17/01/202501:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
17/01/202501:15Business WireOmeros Announces Update on Statistical Analysis of Narsoplimab Pivotal Trial Primary EndpointNASDAQ:OMEROmeros Corporation
20/12/202401:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
20/12/202401:15Business WireOmeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMANASDAQ:OMEROmeros Corporation
11/12/202400:45Business WireOmeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
03/12/202400:45Business WireOmeros Corporation Announces Upcoming Presentations at ASH Annual MeetingNASDAQ:OMEROmeros Corporation
22/11/202401:15Business WireOmeros Corporation Provides Update on Progress Toward BLA ResubmissionNASDAQ:OMEROmeros Corporation
14/11/202408:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
14/11/202408:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
14/11/202408:02Business WireOmeros Corporation Reports Third Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
12/11/202408:11Business WireOmeros Corporation to Announce Third Quarter Financial Results on November 13, 2024NASDAQ:OMEROmeros Corporation
24/10/202423:45Business WireFDA Grants Rare Pediatric Disease Designation to Omeros’ MASP-3 Inhibitor Zaltenibart for Treatment of C3 GlomerulopathyNASDAQ:OMEROmeros Corporation
08/08/202406:08Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:OMEROmeros Corporation
08/08/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
08/08/202406:02Business WireOmeros Corporation Reports Second Quarter 2024 Financial ResultsNASDAQ:OMEROmeros Corporation
06/08/202406:02Business WireOmeros Corporation to Announce Second Quarter Financial Results on August 7, 2024NASDAQ:OMEROmeros Corporation
13/06/202406:48Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
08/06/202407:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
08/06/202407:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
08/06/202407:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
08/06/202407:08Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
08/06/202407:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
08/06/202407:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:OMEROmeros Corporation
04/06/202423:00Business WireOmeros Announces Webcast Details for Annual Meeting of ShareholdersNASDAQ:OMEROmeros Corporation
03/06/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:OMEROmeros Corporation
03/06/202423:00Business WireOmeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028NASDAQ:OMEROmeros Corporation
 Showing the most relevant articles for your search:NASDAQ:OMER

Your Recent History

NYSE
VZ
Verizon Communications
ASX
WDC
Westfield
NYSE
KO
Coca Cola
FX
AUDCAD
AUD vs CAD
ASX
XTO
S&P ASX 100
PM
XAUUSD
Gold vs US Dollar
NYSE
MCD
McDonalds
ASX
ORG
Origin Energy
FTSE
UKX
FTSE 100
ASX
SUN
Suncorp
ASX
XFL
S&P ASX 50
NASDAQ
NVDA
NVIDIA
COIN
ETHUSD
Ethereum
NYSE
JPM
JP Morgan Chase
ASX
FMG
Fortescue
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads